Mitigating alemtuzumab-associated autoimmunity in MS: A "whack-a-mole" B-cell depletion strategy
Conclusions
An anti-CD20 "whack-a-mole" B-cell depletion strategy may serve to mitigate alemtuzumab-associated secondary autoimmunity in MS by reducing the imbalance in B- and T-cell regulatory networks during immune reconstitution. We believe that these observations warrant further investigation.
Classification of evidence
This study provides Class IV evidence that for people with MS, low-dose rituximab following alemtuzumab treatment decreases the risk of alemtuzumab-associated secondary autoimmune diseases.
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Meltzer, E., Campbell, S., Ehrenfeld, B., Cruz, R. A., Steinman, L., Parsons, M. S., Zamvil, S. S., Frohman, E. M., Frohman, T. C. Tags: All Immunology, Autoimmune diseases, All Clinical trials, All Demyelinating disease (CNS), Multiple sclerosis Article Source Type: research
More News: Allergy & Immunology | Autoimmune Disease | Brain | Clinical Trials | Multiple Sclerosis | Neurology | Rituxan | Study